Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: Dna Damage and Activity of Repair Enzymes O6-alkylguanine Alkyltransferase and Poly(adp-Ribose) Polymerase-1.
ER Plummer,MR Middleton,C Jones,A Olsen,I Hickson,P McHugh,GP Margison,G McGown,M Thorncroft,AJ Watson,AV Boddy,AH Calvert,AL Harris,DR Newell,NJ Curtin
DOI: https://doi.org/10.1158/1078-0432.ccr-04-2353
IF: 13.801
2005-01-01
Clinical Cancer Research
Abstract:Purpose: Temozolomide, a DNA methylating agent used to treat melanoma, induces DNA damage, which is repaired by O-6-alkylguanine alkyltransferase (ATase) and poly (ADP-ribose) polymerase-1 (PARP-1)-dependent base excision repair. The current study was done to define the effect of temozolomide on DNA integrity and relevant repair enzymes as a prelude to a phase I trial of the combination of temozolomide with a PARP inhibitor.Experimental Design: Temozolomide (200 mg/m(2) oral administration) was given to 12 patients with metastatic malignant melanoma. Peripheral blood lymphocytes (PBL) were analyzed for PARP activity, DNA single-strand breakage, ATase levels, and DNA methylation. PARP activity was also measured in tumor biopsies from 9 of 12 patients and in PBLs from healthy volunteers.Results: Temozolomide pharmacokinetics were consistent with previous reports. Temozolomide therapy caused a substantial and sustained elevation of N-7-methylguanine levels, a modest and sustained reduction in ATase activity, and a modest and transient increase in DNA strand breaks and PARP activity in PBLs. PARP-1 activity in tumor homogenates was variable (8218 +/- 599 pmol PAR monomer/mg protein) and was not consistently affected by temozolomide treatment.Conclusions: The effect of temozolomide reported here are consistent with those documented in previous studies with temozolomide and similar drug, dacarbazine, demonstrating that a representative patient population was investigated. Furthermore, PARP activity was not inhibited by temozolomide treatment and this newly validated pharmacodynamic assay is therefore suitable for use in a proof-of-principle phase I trial a PARP-1 inhibitor in combination with temozolomide.